The purpose of this research being conducted at Cedars-Sinai is to understand the effects of vaccination against COVID-19 in people with inflammatory bowel disease (Crohn’s disease and ulcerative colitis). To achieve this goal, we aim to recruit a national and local group of adults with IBD who are eligible to receive any available vaccine against COVID-19. Within this group we will evaluate the quality (e.g. antibody levels) of the body’s response to the vaccine, and will be able to share your results with you. We are interested in measuring how different IBD medications might impact the body’s response, especially as compared to people without IBD. We will also learn about the symptoms IBD patients experience after vaccination and how protective vaccination is against future COVID-19 disease.
Participation in this research is completely voluntary. Your decision to participate or not will not affect your medical care and will not impact when you will be offered/eligible to receive a COVID-19 vaccine. Participants can enroll before or after receiving their COVID-19 vaccine and will be in the study for up to one year. If you are able and willing to provide biospecimens (blood and/or saliva) for antibody testing, we will share those results with you.
If you are potentially able and willing to provide one or more in-person biospecimens at Cedars-Sinai Medical Center located in Los Angeles, CA, click the button below to learn more about participating.
If you are not interested or able to in provide an in-person biospecimen, you can still participate in this study by providing remote data through online surveys and optionally a remote sample. To learn more about participating remotely click the button below.
IBD Study Contact
If you have any questions about this study or would like to learn more, please contact the CORALE-V IBD Research Team at Cedars-Sinai at email@example.com or call 310-423-5643.